Join ProKidney Corp. (#PROK) for a virtual KOL event on Tues. May 28 at 8am ET featuring Steven G. Coca, DO, MS (Icahn School of Medicine at Mount Sinai) and Arnold L. Silva, MD, PhD (University of Arizona), who will discuss the unmet medical need and current treatment landscape for patients with moderate to severe chronic kidney disease (#CKD) caused by diabetes.
Register here: https://bit.ly/3yo8xqr
🌟 Join Our Clinical Trial and Make a Difference! 🌟
The Renal Disease Research Institute is seeking participants for an exciting clinical trial aimed at combating serious heart-related complications and preventing the worsening of kidney function. This is your chance to contribute to groundbreaking research and help improve lives!
Study Details:
🔹 Purpose: To determine if Retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function.
🔹 Who Can Join: Adults with a body mass index of 27 kg/m² or higher and Atherosclerotic Cardiovascular Disease and/or chronic kidney disease.
🔹 Duration: The study will last about 5 years.
🔹 Visits: Participants will have up to 27 clinic visits with the study doctor.
Be a part of something big! Your participation could lead to advancements in treatment and offer hope to millions affected by cardiovascular and kidney diseases.
👉 Sign up today! Visit our website for more information and to see if you qualify: https://lnkd.in/dP26XMCD#ClinicalTrial#RenalResearch#HeartHealth#KidneyHealth#JoinUs#MedicalResearch#HealthMatters
🔥 Thrilled to share that our manuscript has been accepted for publication in the Blood Journal. Grateful for the collaborative efforts that make these contributions possible! #nih, #mayoclinic .
Big thanks to Emma Groarke, Yael Kusne MD PhD and the entire team!
In this paper, we explore questions about thrombotic manifestations in #VEXAS! Check it out.
Key takeaways:
✔ VTE is prevalent in VEXAS, occurring in over 40% of patients with frequent recurrences; remarkably, it doesn't link to increased mortality.
✔ Due to the high VTE risk, VEXAS patients should undergo thromboprophylaxis in high-risk settings, unless contraindicated.
🌟 🌟 THE MORE YOU KNOW 🌟 🌟
A study completed by Pekacka-Egli in 2021 showed that FEES was completed on Day 5 of admission to the post-acute care facility in patients following strokes, 60% experienced favorable diet upgrades. They also showed significantly lower pneumonia rates and a shorter length of stay in this cohort. "Instrumental diagnostics during the early convalescence period of stroke patients lead to clinically relevant changes to the diet and lower rates of pneumonia. Our findings underline the need for regular and qualitative dysphagia diagnostics during stroke rehabilitation."
Link to article https://lnkd.in/g4HpYWAM
🚀 Exciting News in Multiple Sclerosis Research!
Roche's Elecsys neurofilament light chain (NfL) test, designed to detect disease activity in adults with relapsing-remitting or secondary progressive MS, has received FDA breakthrough device designation.
With an estimated 2.8 million people living with MS, Roche aims to address testing accessibility challenges and improve patient outcomes.
The potential of Elecsys NfL lies in its minimally invasive blood draw, offering rapid results for optimizing treatment strategies.
https://lnkd.in/e5ghGP4t
📰 Follow Practical Patient Care to receive the latest healthcare news daily that is important to you and to subscribe to our weekly newsletter
#practicalpatientcare#MultipleSclerosis#RocheInnovation#NeurologyBreakthroughs
Com a importante colaboração como coautores da equipa de Medicina Interna do CRe de Doenças Hereditárias do Metabolismo da ULS Santa Maria.
“Natural history of three late-diagnosed classic Galactosemia patients”
Dulce Quelhas, Sandra D.K. Kingma, An I. Jonckheere , Claudia S. Smeets-Peels, Daniel Costa Gomes, José Duro, Anabela Oliveira, Gert Matthijs, Laura K.M. Steinbusch, Jack Jaeken, Isabel Rivera, Estela Rubio-Gozalbo
Abstract
The authors report the natural history of three patients with late-diagnosed Classic Galactosemia (CG) (at 16, 19 and 28 years). This was due to a combination of factors: absence of neonatal screening, absence of some typical acute neonatal symptoms, and negative galactosemia screening. This report underlines the value of neonatal screening and the importance of further diagnostic testing in case of late-onset manifestations.
MD MSc EDIC | Intensive Care Medicine and Internal Medicine Specialist | Faculty of Medicine Invited Assistant
Rethinking diagnosis. A great example of the importance of a multidisciplinary approach between clinic, biochemistry and genetic in complex metabolic disorders.
The term “split-brain” refers to patients in whom the corpus callosum has been cut for the alleviation of medically intractable epilepsy. Since the earliest reports by van Wagenen and Herren (1940) and Akelaitis (1941, 1943) on the repercussions of a split-brain, two narratives have emerged.
#https://lnkd.in/dZ3hP9g7National Center for Biotechnology Information (NCBI)Centers for Disease Control and PreventionFDAWorld Health OrganizationUSAIDAIMS EduTech
the empirical common ground, to delineate the different interpretations, and to identify the remaining questions. In short, callosotomy leads to a broad breakdown of functional integration ranging from perception to attention. However, the breakdown is not absolute as several processes, such as action control, seem to remain unified. Disagreement exists about the responsible mechanisms for this remaining unity. The main issue concerns the first-person perspective of a split-brain patient.
View the #NeuPSIG2023 Scientific Program; learn about the leading meeting for the latest research and developments in understanding the mechanisms, assessment, prevention, and treatment of neuropathic pain, and plan your agenda. https://bit.ly/3oYcRZf
https://clinfinite.com/
🎗World Sickle Cell Day, observed on June 19th each year, raises awareness about sickle cell disease (SCD), a genetic blood disorder affecting millions globally. It emphasizes the importance of early diagnosis, treatment, and management to improve the quality of life for those living with SCD.
🎗The day aims to educate communities about the challenges faced by individuals with SCD and their families, including pain crises, organ damage, and reduced life expectancy. It also encourages governments and healthcare systems to prioritize resources for research, access to care, and support services.
🎗Through advocacy and education, World Sickle Cell Day fosters solidarity and understanding among affected individuals, healthcare professionals, policymakers, and the general public. It underscores the need for continued efforts in research and medical advancements to find a cure or more effective treatments for this complex disease.
🎗Ultimately, World Sickle Cell Day serves as a beacon of hope for patients and caregivers, promoting a future with better outcomes and improved quality of life.
#World#Sickle#CellDay#clinfinitesolutions#Scd#clinicaldevelopment#cro#clinicalresearch#biospecimen
In a recent randomized trial published in JAMA, researchers explored the potential benefits of acetaminophen in sepsis management. The study involved 447 patients with sepsis accompanied by respiratory or circulatory organ failure and compared the outcomes of patients receiving acetaminophen (1 gram every six hours for five days) to those receiving a placebo.
The findings revealed no significant difference in the number of days patients were alive and free of organ support between the acetaminophen and placebo groups. Interestingly, the incidence of acute respiratory distress syndrome (ARDS) was notably lower in the acetaminophen group (2% compared to 9%).
These preliminary results are promising; however, further research is required to establish the routine use of acetaminophen in patients with sepsis and organ dysfunction.
#SepsisResearch#CriticalCare#MedicalResearch#Acetaminophen#ClinicalTrials#JAMAPublication#OrganFailure
In our recent study, we investigated the risk of adjacent-level fractures following interventions for osteoporotic vertebral compression fractures (VCFs). Through randomized controlled trials (RCTs), we aimed to compare the outcomes of vertebroplasty and kyphoplasty against the natural progression of the disease.
Key Findings:
- RCTs were conducted to evaluate the risk of adjacent-level fractures post-intervention.
- Results indicated no significant difference in the incidence of adjacent compression fractures between patients who underwent vertebroplasty or kyphoplasty and those who followed the natural disease course.
- This provides robust evidence that interventional treatments such as vertebroplasty and kyphoplasty do not elevate the risk of subsequent adjacent fractures.
These findings are crucial for informing clinical decisions and reassuring both practitioners and patients regarding the safety of these common interventional treatments for VCFs. Our study underscores that opting for vertebroplasty or kyphoplasty does not compromise the structural integrity of adjacent vertebrae.
• The link to our study:
https://lnkd.in/d4qr-uFk#Osteoporosis#VertebralFractures#RCT#Vertebroplasty#Kyphoplasty#SpineHealth#ClinicalResearch